Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives $21.00 Average Target Price from Brokerages

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $21.00.

TLX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Citigroup initiated coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They set a “buy” rating and a $22.00 target price for the company. Finally, UBS Group reduced their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd.

Hedge Funds Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC lifted its stake in Telix Pharmaceuticals by 67.3% in the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock worth $403,000 after acquiring an additional 16,945 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Telix Pharmaceuticals in the 3rd quarter worth about $243,000. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the period. IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $213,000. Finally, Jane Street Group LLC purchased a new position in shares of Telix Pharmaceuticals during the second quarter valued at about $564,000.

Telix Pharmaceuticals Trading Down 3.1%

Shares of TLX stock opened at $9.51 on Friday. Telix Pharmaceuticals has a fifty-two week low of $8.93 and a fifty-two week high of $30.36. The stock has a 50 day moving average price of $10.10 and a two-hundred day moving average price of $13.33.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.